DE69733478D1 - Ether-muskarinantagonisten - Google Patents
Ether-muskarinantagonistenInfo
- Publication number
- DE69733478D1 DE69733478D1 DE69733478T DE69733478T DE69733478D1 DE 69733478 D1 DE69733478 D1 DE 69733478D1 DE 69733478 T DE69733478 T DE 69733478T DE 69733478 T DE69733478 T DE 69733478T DE 69733478 D1 DE69733478 D1 DE 69733478D1
- Authority
- DE
- Germany
- Prior art keywords
- optionally substituted
- alkyl
- formula
- compounds
- disclosed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70072296A | 1996-08-15 | 1996-08-15 | |
| US700722 | 1996-08-15 | ||
| PCT/US1997/013894 WO1998006697A1 (en) | 1996-08-15 | 1997-08-13 | Ether muscarinic antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69733478D1 true DE69733478D1 (de) | 2005-07-14 |
| DE69733478T2 DE69733478T2 (de) | 2005-11-03 |
Family
ID=24814614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69733478T Expired - Fee Related DE69733478T2 (de) | 1996-08-15 | 1997-08-13 | Ether-muskarinantagonisten |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0922029B1 (de) |
| JP (1) | JP3390179B2 (de) |
| KR (1) | KR20000029976A (de) |
| CN (1) | CN1155574C (de) |
| AT (1) | ATE297381T1 (de) |
| AU (1) | AU732096B2 (de) |
| BR (1) | BR9711061A (de) |
| CA (1) | CA2263167C (de) |
| CZ (1) | CZ43399A3 (de) |
| DE (1) | DE69733478T2 (de) |
| ES (1) | ES2241053T3 (de) |
| HU (1) | HUP9904363A3 (de) |
| IL (1) | IL128524A0 (de) |
| NO (1) | NO990671L (de) |
| NZ (1) | NZ334017A (de) |
| PL (1) | PL331536A1 (de) |
| SK (1) | SK20199A3 (de) |
| TR (1) | TR199900314T2 (de) |
| WO (1) | WO1998006697A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU762726B2 (en) * | 1998-03-31 | 2003-07-03 | Acadia Pharmaceuticals, Inc. | Compounds with activity on muscarinic receptors |
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| WO2000038672A2 (en) | 1998-12-23 | 2000-07-06 | Orphan Medical, Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| ES2246233T3 (es) * | 1999-05-04 | 2006-02-16 | Schering Corporation | Derivados de piperidina utiles como antagonistas de ccr5. |
| US6635646B1 (en) | 1999-05-04 | 2003-10-21 | Schering Corporation | Pegylated interferon alfa-CCR5 antagonist combination HIV therapy |
| US6387930B1 (en) | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| EA009647B1 (ru) | 2001-05-11 | 2008-02-28 | Биовитрум Аб | Арилсульфонамидные соединения и их применение для лечения ожирения и диабета типа ii |
| US7718650B2 (en) | 2001-05-11 | 2010-05-18 | Biovitrum Ab | Aryl sulfonamide compounds for treating obesity |
| BR0210733A (pt) * | 2001-07-02 | 2004-07-20 | Astrazeneca Ab | Derivados de piperidina de utilidade úteis como moduladores da atividade do receptor de quimocina |
| GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
| KR100579813B1 (ko) * | 2001-10-16 | 2006-05-12 | 주식회사 에스티씨나라 | 피페리딘 유도체, 이의 제조방법 및 이를 포함하는 치매치료용 약학적 조성물 |
| DE10201550A1 (de) * | 2002-01-17 | 2003-07-31 | Merck Patent Gmbh | Phenoxy-Piperidine |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SI1514542T1 (sl) * | 2002-06-14 | 2012-06-29 | Toyama Chemical Co Ltd | Farmacevtska sestava, vsebujoäśa takrin ali donepezil za izboljĺ anje moĺ˝ganske funkcije |
| SE0202838D0 (sv) * | 2002-09-24 | 2002-09-24 | Astrazeneca Ab | Chemical compounds |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| SE0302956D0 (sv) * | 2003-11-07 | 2003-11-07 | Astrazeneca Ab | Chemical compounds |
| EP1888527A1 (de) * | 2005-05-27 | 2008-02-20 | AstraZeneca AB | Piperidine zur behandlung von chemokinvermittelten krankheiten |
| TW200722419A (en) * | 2005-05-27 | 2007-06-16 | Astrazeneca Ab | Chemical compounds |
| CA2615650A1 (en) | 2005-07-21 | 2007-01-25 | Astrazeneca Ab | Novel piperidine derivatives |
| DE102008008838A1 (de) | 2008-02-13 | 2009-08-20 | Bayer Healthcare Ag | Cycloalkoxy-substituierte 4-Phenyl-3,5-dicyanopyridine und ihre Verwendung |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| IN2012DN06631A (de) | 2010-02-16 | 2015-10-23 | Pfizer | |
| WO2017157873A1 (en) | 2016-03-17 | 2017-09-21 | F. Hoffmann-La Roche Ag | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018112840A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| WO1997010212A1 (en) * | 1995-09-15 | 1997-03-20 | Neurosearch A/S | Piperidine compounds as calcium channel blockers |
-
1997
- 1997-08-13 JP JP50985498A patent/JP3390179B2/ja not_active Expired - Fee Related
- 1997-08-13 KR KR1019997001227A patent/KR20000029976A/ko not_active Application Discontinuation
- 1997-08-13 CN CNB971985588A patent/CN1155574C/zh not_active Expired - Fee Related
- 1997-08-13 BR BR9711061A patent/BR9711061A/pt unknown
- 1997-08-13 DE DE69733478T patent/DE69733478T2/de not_active Expired - Fee Related
- 1997-08-13 CA CA002263167A patent/CA2263167C/en not_active Expired - Fee Related
- 1997-08-13 TR TR1999/00314T patent/TR199900314T2/xx unknown
- 1997-08-13 NZ NZ334017A patent/NZ334017A/xx unknown
- 1997-08-13 SK SK201-99A patent/SK20199A3/sk unknown
- 1997-08-13 AT AT97937152T patent/ATE297381T1/de not_active IP Right Cessation
- 1997-08-13 AU AU39732/97A patent/AU732096B2/en not_active Ceased
- 1997-08-13 CZ CZ99433A patent/CZ43399A3/cs unknown
- 1997-08-13 IL IL12852497A patent/IL128524A0/xx unknown
- 1997-08-13 WO PCT/US1997/013894 patent/WO1998006697A1/en active IP Right Grant
- 1997-08-13 ES ES97937152T patent/ES2241053T3/es not_active Expired - Lifetime
- 1997-08-13 EP EP97937152A patent/EP0922029B1/de not_active Expired - Lifetime
- 1997-08-13 PL PL97331536A patent/PL331536A1/xx unknown
- 1997-08-13 HU HU9904363A patent/HUP9904363A3/hu unknown
-
1999
- 1999-02-12 NO NO990671A patent/NO990671L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1155574C (zh) | 2004-06-30 |
| HUP9904363A3 (en) | 2000-12-28 |
| AU3973297A (en) | 1998-03-06 |
| EP0922029A1 (de) | 1999-06-16 |
| BR9711061A (pt) | 1999-08-17 |
| HUP9904363A2 (hu) | 2000-11-28 |
| WO1998006697A1 (en) | 1998-02-19 |
| JP3390179B2 (ja) | 2003-03-24 |
| KR20000029976A (ko) | 2000-05-25 |
| CA2263167A1 (en) | 1998-02-19 |
| NO990671L (no) | 1999-04-15 |
| AU732096B2 (en) | 2001-04-12 |
| IL128524A0 (en) | 2000-01-31 |
| ATE297381T1 (de) | 2005-06-15 |
| JP2000500786A (ja) | 2000-01-25 |
| ES2241053T3 (es) | 2005-10-16 |
| CA2263167C (en) | 2006-02-14 |
| DE69733478T2 (de) | 2005-11-03 |
| NZ334017A (en) | 2000-04-28 |
| NO990671D0 (no) | 1999-02-12 |
| EP0922029B1 (de) | 2005-06-08 |
| PL331536A1 (en) | 1999-07-19 |
| CZ43399A3 (cs) | 1999-07-14 |
| TR199900314T2 (xx) | 1999-05-21 |
| SK20199A3 (en) | 2000-03-13 |
| CN1232453A (zh) | 1999-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69733478D1 (de) | Ether-muskarinantagonisten | |
| MY133992A (en) | Muscarinic antagonists | |
| NO990551L (no) | Piperidin- og piperazinderivater, og deres anvendelse som muskarine antagonister | |
| PT912515E (pt) | Piperidinas 1,4-di-substituidas como antagonistas muscarinicos | |
| EA200100553A1 (ru) | Замещенные бициклические производные, полезные в качестве противораковых агентов | |
| DE69715865D1 (de) | Muscarin-antagonisten | |
| DE69631370D1 (de) | Benzylpiperidine und -piperazine als muscarinantagonisten | |
| PL361361A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| RU2004126957A (ru) | Пиперидиновые производные | |
| PL361282A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| MY133445A (en) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivetives | |
| ES2087038A1 (es) | Nuevas piperidinas con actividad antagonista del paf. | |
| CA2336000A1 (en) | N-substituted piperazines and 1,4-disubstituted piperidines | |
| HUT57773A (en) | Process for produicng n-(aminocarbonyl)-carbamates related to physostigmine, as well as pharmaceutical compositions comprising such compounds | |
| NZ543068A (en) | Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them | |
| ATE420860T1 (de) | N-substituierte amide als nk1 rezeptor antagonisten | |
| RU2003105827A (ru) | Средства против слабоумия, содержащие производные 2-арил-8-оксодигидропурина, в качестве активного ингредиента | |
| ECSP003505A (es) | Derivados de 4-fenil- pirimidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |